Popular Trials
Immune Checkpoint Inhibitor
Combination Therapy + Radiation for Glioblastoma
This trial is testing a combination of treatments including a new drug, radiation therapy, and other medications for patients with aggressive brain cancer that has returned. The goal is to boost the body's immune system to better fight the cancer, shrink tumors, and help patients live longer.
Popular Filters
Trials for Diffuse Intrinsic Pontine Glioma Patients
Radiation
Rhenium Liposome Treatment for Brain Cancer
This trial is testing a new cancer treatment to see if it is safe and effective. It uses a modified Fibonacci dose escalation, which means it starts with a small dose and increases the dose each time until the maximum tolerated dose is reached. The starting absorbed dose is 1mCi in a volume of 0.660mL.
Trials for Metastatic Patients
Radiation
Rhenium Liposome Treatment for Brain Cancer
This trial is testing a new cancer treatment to see if it is safe and effective. It uses a modified Fibonacci dose escalation, which means it starts with a small dose and increases the dose each time until the maximum tolerated dose is reached. The starting absorbed dose is 1mCi in a volume of 0.660mL.
Molecular Profiling
Molecular Profiling for Brain Tumor
This trial will test a new treatment approach for children with High-grade gliomas HGG that is based on each patient's tumor gene expression, whole-exome sequencing (WES), targeted panel profile (UCSF 500 gene panel), and RNA-Seq.
Behavioral Intervention
Telehealth Consultations for Brain Cancer
This trial will create an Early START visit for patients with high grade gliomas to discuss end of life wishes soon after their initial oncology visit. A checklist and pre-visit guide will be used to help guide the visit for both the provider and patient.
Trials for IDH Positive Patients
Procedure
MRE Scan for Brain Tumor Assessment
This trial uses magnetic resonance elastography (MRE) to estimate tissue stiffness in tissue affected by radiation treatment or tumor recurrence in patients with gliomas. MRE may help doctors more accurately diagnose the disease and/or assess the disease's response to treatment.
Trials for BRAF Positive Patients
Chemotherapy
PF-07799544 for Cancer
This trial tests a new cancer medicine, PF-07799544, taken regularly as a tablet. It is for people with advanced solid tumors who haven't responded to other treatments. The medicine may be used alone or with other drugs to improve its effectiveness.
Chemotherapy
PF-07799933 for Advanced Cancers
This trial tests a new medicine, PF-07799933, for people with advanced solid tumors that have a specific gene issue and haven't responded to other treatments. Participants will take PF-07799933 as a tablet regularly, and some may also take binimetinib or receive cetuximab shots. The goal is to see if these medicines are safe and effective.
Kinase Inhibitor
Vemurafenib for Pediatric Brain Cancer
This trial is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of vemurafenib in children with recurrent or refractory gliomas containing the BRAFV600E or BRAF Ins T mutation.
Kinase Inhibitor
Selumetinib for Pediatric Brain Cancer
This trial is testing a new drug to treat young patients with brain cancer that has come back or does not respond to treatment. The drug may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Vinca alkaloids
Vinblastine + Bevacizumab for Brain Tumor
This trial is testing if adding Bevacizumab to Vinblastine helps children with worsening brain tumors more than using Vinblastine alone. Vinblastine is given regularly, and Bevacizumab is added periodically for several months. Bevacizumab is an anti-VEGF antibody approved for treating various cancers and has been studied for use in children with brain tumors.
View More Related Trials
Frequently Asked Questions
Introduction to glioma
What are the top hospitals conducting glioma research?
In the battle against glioma, a formidable type of brain tumor, several hospitals are leading the charge in groundbreaking clinical trials. Washington University School of Medicine in Saint Louis takes center stage with an impressive 12 active glioma trials and a remarkable history of 56 completed trials since their first recorded experiment back in 1998. Meanwhile, Children's National Medical Center in Washington D.C., known for its expertise in pediatric care, is making significant strides with nine ongoing glioma trials and a notable record of conducting 68 trials dedicated to this challenging condition since their inaugural investigation in 2001.
Boston's Dana-Farber Cancer Institute joins the ranks as well, contributing heavily to glioma research with nine active clinical trials and an admirable tally of 74 previously conducted studies dating back to their pioneering trial in 1997. Across state lines at Memorial Sloan Kettering Cancer Center located in New york City, researchers are hard at work conducting nine ongoing glioma trials while having accomplished an impressive total of 58 previous investigations since initiating their first study on this complex brain tumor subtype in 2002.
Lastly but certainly not least important is Cincinnati Children's Hospital Medical Center situated within Ohio; although smaller-scale compared to some counterparts mentioned earlier they play vital roles too - currently hosting seven active glioma clinical tests while also holding solid contribution through fifty-seven prior experiments starting from same timeline i.e. year2002.
These institutions embody hope for patients battling against the challenges presented by gliomas while actively paving new paths towards improved treatments and ultimately a cure. Their dedication to understanding this devastating disease brings us closer each day towards breakthroughs that promise brighter futures for those affected by these aggressive brain tumors worldwide
Which are the best cities for glioma clinical trials?
When it comes to glioma clinical trials, several cities emerge as leading hubs for cutting-edge research. New york City takes the lead with 36 active trials focusing on treatments like PF-07799933 and Bevacizumab. Houston, Texas follows closely behind with 29 ongoing studies exploring interventions such as ONC201 Once Weekly Group and AG881. Los Angeles, California is also a prominent city for glioma clinical trials, offering 28 active studies investigating options like Subprotocol C2 and AG-120. Each of these cities provides individuals with glioma access to a diverse range of innovative clinical trials that strive to advance treatment options and improve outcomes.
Which are the top treatments for glioma being explored in clinical trials?
Glioma research is at the forefront of medical investigations, with several promising treatments currently being explored in clinical trials. Leading the charge is pembrolizumab, which has shown potential in two active trials and six all-time glioma trials since its introduction in 2015. Another contender making waves is retifanlimab, engaged in two ongoing trials after its listing last year. Nivolumab joins the race with impressive results from two active trials and a total of 15 all-time glioma trials since 2015. Finally, AG-120 enters the scene with two active glioma trials under its belt since it was introduced back in 2014. The progress made through these clinical trials brings hope to patients battling this challenging disease as researchers strive towards finding effective treatment options for gliomas worldwide
What are the most recent clinical trials for glioma?
Recent clinical trials have brought renewed hope for patients with glioma, a type of brain tumor. One notable trial is focused on APG-157, which has entered Phase 1 and Phase 2 studies as of September 15, 2023. Another promising development involves safusidenib at a dose of 500mg bid in a Phase 2 trial that commenced on May 26, 2023. Additionally, the combination of abemaciclib and temozolomide is being evaluated in Phase 1 trials since April7,2023. Other studies include surgical resection coupled with pharmacodynamic assays and methimazole in their investigation (Phase2), starting from January30th ,2023; and ONC201 Once Weekly Group (Phase3) commencing from January23rd ,2023.
What glioma clinical trials were recently completed?
Several recent clinical trials have made significant strides in the field of glioma research, offering new hope for patients battling this challenging brain cancer. In November 2020, Dana-Farber Cancer Institute concluded a successful trial investigating Perampanel's potential as a treatment option. Prelude Therapeutics also completed their PRT811 trial in November 2019, while James Mountz wrapped up their study on 18F-fluciclovine in October 2019. These advancements highlight the ongoing dedication of researchers and institutions to finding effective therapies against glioma.